Advertisement

Topics

[News] Potential biomarker for acute myeloid leukaemia therapy

21:54 EDT 29 Jun 2017 | The Lancet

Gemtuzumab ozogamicin, a CD33-targeted therapy for acute myeloid leukaemia (AML), significantly improves outcomes compared with standard chemotherapy in patients with a specific CD33 splicing polymorphism genotype, according to a recent study.

Original Article: [News] Potential biomarker for acute myeloid leukaemia therapy

NEXT ARTICLE

More From BioPortfolio on "[News] Potential biomarker for acute myeloid leukaemia therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...